Mzzchj4ftw2vrygvha3j 2017 06 29 11 10 50

ACT Genomics

Taipei, TW

We are the world's leading cancer solution provider. Based in Taiwan, we also provide effective services through our offices in Singapore, Hong Kong, Shanghai and Tokyo. Joint by experts from the field of cancer biology, cancer genomics and bioinformatics, we provide optimal cancer treatment plan, cancer relapse and drug resistance monitoring as well as cancer risk assessment and immunotherapy evaluation. We are dedicated to provide every cancer patient personalized genomic information based-treatment plans through our cutting-edge Next Generation Sequencing (NGS) platform, medical report and integrated services.

ACT Genomics has not listed any services.

Targeted Cancer Gene Panel
Price on request
Request a quote for more information about this service.
Comprehensive Cancer Gene Panel
Price on request

Next Generation Sequencing for Solid Tumor
Our service ACTOnco sequences 440 cancer related genes covering major key cancer signaling pathways for targeted therapy in our ISO17025 and CAP accredited lab. Signaling pathways in the panel include: P53 signaling pathway, Ras signaling pathway, P13K-Akt signaling pathway, MicroRNAs... Show more »

Next Generation Sequencing for Solid Tumor
Our service ACTOnco sequences 440 cancer related genes covering major key cancer signaling pathways for targeted therapy in our ISO17025 and CAP accredited lab. Signaling pathways in the panel include: P53 signaling pathway, Ras signaling pathway, P13K-Akt signaling pathway, MicroRNAs in cancer, MAPK sinaling pathway, mTOR signaling pathway, HIF-1 signaling pathway.
With the completed tumor genomic profile, we generate a comprehensive that effectively maximizes the cancer patient’s treatment options. Customized panels are available upon discussion.

ACTOnco+ is most suitable for: Patients with solid tumors, Patients newly diagnosed with cancer, Patients to be treated with chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy for the first time, Patients with recurrence or metastasis, Patients with resistance to existing treatment

Sample types: FFPE (formalin-fixed and paraffin-embedded) tissue, Excessive body fluids associated with cancers (such as lung water or ascites)

Turnaround time:
14 calendar days after samples are received

« Show less
Oncology
FFPE tissue
Next Generation Sequencing
Colorectal cancer
Oncology
Immunooncology
Breast Cancer
body fluid
Lung Cancer
Gastric Cancer
Neoantigen Prediction
Price on request

ACTOnco also serves as a service that calculates the mutation burden which predicts the patient’s response to immunotherapy. Signaling pathways in this panel include: T cell receptor signaling pathway, B cell receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, chemokine signaling... Show more »

ACTOnco also serves as a service that calculates the mutation burden which predicts the patient’s response to immunotherapy. Signaling pathways in this panel include: T cell receptor signaling pathway, B cell receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, chemokine signaling pathway, Jak-STAT signaling pathway, Toll-like receptor signaling pathway, NF-kappa B signaling pathway and Wnt signaling pathway.

« Show less
Immunology
Oncology
Next Generation Sequencing
Genomics
Immunooncology
Liquid Biopsy
Price on request

Our liquid biopsy solution ACTMonitor™, a 50-gene panel, provides reliable information for the assessment on treatment response and the detection of potential drug resistance and cancer recurrence. Liquid biopsy is a non-invasive alternative to surgical biopsies through a simple blood draw, from which circulating tumor DNA (ctDNA)... Show more »

Our liquid biopsy solution ACTMonitor™, a 50-gene panel, provides reliable information for the assessment on treatment response and the detection of potential drug resistance and cancer recurrence. Liquid biopsy is a non-invasive alternative to surgical biopsies through a simple blood draw, from which circulating tumor DNA (ctDNA) is analyzed. ctDNA consists of fragments of tumor DNA that have been released into the blood stream. Therefore, obtaining cancer patients’ ctDNA may help us understand their tumor even when tissue biopsies are not available. Customized panels are available upon discussion.
ACTMonitor is most suitable for: Who are unable to undergo surgery, Who have developed drug resistance, With risk of cancer recurrence, Who wish to monitor treatment response

Turnaround time:
14 calendar days after samples are received

« Show less
Oncology
Next Generation Sequencing
Blood
Genomics
Oncology
Immunooncology
Immunotherapy Screening
Price on request

Patient outcome for immunotherapy
ACTImmune is a service that determines the feasibility of using checkpoint blockade as a cancer treatment by conducting a whole exome sequencing with NGS. Patients treated with checkpoint inhibitors targeting PD-1 and CTLA-4 respond better to immunotherapy if their tumors harbor a high... Show more »

Patient outcome for immunotherapy
ACTImmune is a service that determines the feasibility of using checkpoint blockade as a cancer treatment by conducting a whole exome sequencing with NGS. Patients treated with checkpoint inhibitors targeting PD-1 and CTLA-4 respond better to immunotherapy if their tumors harbor a high neoantigen load. Our report provides a list of the identified neoantigens and genomic alterations in cancer-related genes, which enables adaptive T cell transfer.

Sample types: FFPE (formalin-fixed and paraffin-embedded) tissue, Excessive body fluids associated with cancers (such as lung water or ascites)

Turnaround time:
30 calendar days after samples are received

« Show less
Immunology
Oncology
Next Generation Sequencing
Genomics
Oncology
Immunooncology
Drug Development
Price on request

Under our CAP-accredited next generation sequencing laboratory, along with an experienced in-house bioinformatics team, ACT Genomics understands the challenges faced by pharmaceuticals today and is confident to provide services to accelerate the process of oncology drug development and commercialization. With the superior... Show more »

Under our CAP-accredited next generation sequencing laboratory, along with an experienced in-house bioinformatics team, ACT Genomics understands the challenges faced by pharmaceuticals today and is confident to provide services to accelerate the process of oncology drug development and commercialization. With the superior sensitive and have a quick turn-around time, ACT Genomics is devoted to provide clinical-grade, reliable results for drug development. Our current biopharma projects include:
 - Investigational assay development
 - Biomarker identification
 - Patient stratification
 - Comprehensive cancer molecular analysis
 - Consultation

« Show less
Clinical Research
Price on request
Request a quote for more information about this service.
Clinical Laboratory Services
Price on request
Request a quote for more information about this service.
Clinical Molecular Diagnostics
Price on request
Request a quote for more information about this service.
Gene Panel Testing
Price on request
Request a quote for more information about this service.
Biology
Price on request
Request a quote for more information about this service.
Biochemistry & Molecular Biology
Price on request
Request a quote for more information about this service.
Protein Services
Price on request
Request a quote for more information about this service.
Antibody Services
Price on request
Request a quote for more information about this service.
Pharmacology & Toxicology
Price on request
Request a quote for more information about this service.
Bioanalysis
Price on request
Request a quote for more information about this service.
Drug Discovery & Development
Price on request
Request a quote for more information about this service.

ACT Genomics has not received any ratings.

Be the first to endorse ACT Genomics

Endorse this lab